
Topic
Immunotherapy
Podcasts
Tumor Board # 87Oct 27, 2026Diagnosis & Management of Advanced HER2-Negative Upper GI Cancers

Five years ago, first-line treatment for advanced HER2-negative gastroesophageal cancer meant chemotherapy; today claudin 18.2, PD-L1, and mismatch repair status shape the plan, often for a patient who cannot afford to wait for the results. On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Kate Baker interviews medical oncologists Dr. Ronan Hsieh and Dr. Dani Castillo about the diagnosis and management of advanced HER2-negative upper GI cancers. They discuss the biomarker workup at diagnosis, next-generation sequencing and liquid biopsy, when to biopsy metastatic sites, and why both guests start chemotherapy before every result is available.
Tumor Board # 85Oct 13, 2026Perioperative Management in Upper GI Cancers

How do you choose between perioperative chemotherapy and trimodality therapy for a patient with localized upper GI cancer, and what has the newest data actually settled? On this episode of BackTable Tumor Board, host Dr. Kate Baker interviews Dr. Dani Castillo, a medical oncologist at City of Hope in Duarte, California, and Dr. Alexandra Gangi, a gastrointestinal surgical oncologist at Cedars-Sinai in Los Angeles, about everything that happens between a new diagnosis and a resection in localized esophageal, gastroesophageal junction and gastric cancer. They cover diagnostic workup, Siewert classification, staging laparoscopy, histology, biomarker testing, surgical candidacy, and the challenges of nutrition and prehabilitation.
Tumor Board # 82Sep 22, 2026Advances in Perioperative Colorectal Cancer Management

How much of perioperative colorectal cancer management has changed in just one year, and what does it mean for patient care? On this episode of BackTable Tumor Board, Dr. Jun Gong is joined by Dr. Ibrahim Sahin and Dr. Alexandra Gangi to review the latest practice-changing data in colon and rectal cancer. They discuss observation versus maintenance immunotherapy in MSI-high disease, the CHALLENGE trial's surprising results on exercise and disease-free survival, and the evolving role of ctDNA and local therapies after liver metastasis resection.
ENT & Allergy # 290Sep 1, 2026Managing Sjogren's in ENT & Allergy Clinics

With no FDA-approved therapies for Sjögren’s disease, how can ENTs and allergists provide effective care and keep up with emerging treatments? On this episode of BackTable ENT & Allergy, Dr. Basil Kahwash interviews Dr. Kara Wada, a Columbus-based allergist, immunologist, and lifestyle medicine physician, about her personal and clinical experience with Sjögren’s disease. They discuss the major gaps in current treatment, the evolving role of otolaryngologists and allergists in multidisciplinary care, and the new therapies on the horizon.
Tumor Board # 75Aug 4, 2026Applying CheckMate 8HW: Practical Updates for MSI-High CRC

Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor Board, medical oncologist Jun Gong interviews Dr. Cathy Eng about updates from the phase III CheckMate-8HW trial in centrally confirmed MSI-high/dMMR metastatic colorectal cancer, comparing nivolumab/ipilimumab, nivolumab, and chemotherapy. They discuss initial findings demonstrating improved progression-free survival and response rates with combination immunotherapy, as well as safety considerations and how comorbidities and frailty guide the choice between single-agent and combination regimens.
Tumor Board # 74Jul 28, 2026Systemic Therapy Strategies for Treating Neuroendocrine Tumors

What first-line therapies should be considered for patients with higher-grade, metastatic neuroendocrine tumors (NETs)? In this new episode of BackTable Tumor Board, Drs. Lingling Du, Chih-Yi Liao, and Robert Ramirez discuss the use of systemic or radioligand therapies for metastatic well-differentiated NETs.
Industry # 103Jun 30, 2026Staying Updated in Allergy & Immunology

How do you protect your time, stay current, and thrive after leaving academic medicine for private practice in a fast-evolving allergy and immunology specialty? In this episode of BackTable Industry, host Anish Parikh talks with Dr. Basil Kahwash, an allergist-immunologist, about his journey from internal medicine training through academic medicine at Vanderbilt and back to community practice in Columbus. They discuss the challenges of protecting time, adapting to higher patient volumes, and staying up to date as allergy and immunology rapidly evolve.
ENT & Allergy # 279Jun 23, 2026Collaborative Care in Chronic Sinusitis & Allergies

When should recurrent sinus infections trigger an allergy or immune workup? In this episode of the BackTable ENT & Allergy Podcast, Dr. Karen Kaufman of Kaufman Allergy, Asthma, & Immunology in Vienna, Virginia, sits down with Dr. Ashley Agan to discuss chronic sinusitis evaluation, allergy testing, immunotherapy, immune deficiency screening, and building a private practice.
Vascular & IR # 655Jun 16, 2026Managing Large Liver Tumors: Strategies & Challenges

How is Y90 radioembolization rewriting the rules for managing large HCC tumors and creating new curative-intent therapeutic pathways where palliation was once deemed the only option? In this episode of the 2026 HCC Creator Weekend™, interventional radiologists Dr. Chris Malone (WashU), Dr. Tyler Sandow (Ochsner Health), and Dr. Beau Toskich (Mayo Clinic Florida) join host Dr. Zach Berman for a case-based discussion on advanced dosimetric strategies and embolization approaches for large and complex HCC lesions.
Urology # 305Jun 2, 2026Immune Therapy Innovations for BCG Unresponsive Cancer

Ready to move beyond “one-size-fits-all” for BCG-unresponsive NMIBC? In this episode of BackTable Urology, Dr. Ruchika Talwar hosts Dr. Sam Chang to discuss the evolving treatment landscape for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). They explore why BCG may fail, the science and clinical rationale behind new immunotherapies and gene therapies, practical approaches to patient selection, treatment sequencing, and surveillance, and the value of emerging biomarkers, empowering urologists to make more informed, personalized decisions in complex cases of NMIBC.
Tumor Board # 59May 12, 2026Evolving Treatment Paradigms in Hepatocellular Carcinoma: What's on the Horizon?

With new systemic and liver-directed approaches under investigation, which targets and treatment strategies are most likely to shape HCC care? In this final episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi focus on the future of hepatocellular carcinoma beyond established PD-1/CTLA-4 regimens.
Tumor Board # 58May 5, 2026Advanced Hepatocellular Carcinoma: Navigating Second-Line Therapy Options

When first-line treatment for advanced hepatocellular carcinoma (HCC) fails and the disease progresses, what options are available for second-line therapy? In this episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi explore the uncertain landscape of second-line treatment after first-line immunotherapy, such as atezolizumab and bevacizumab or the STRIDE regimen, including practical considerations for choosing which second-line therapy to use.
Tumor Board # 57Apr 28, 2026First-Line Therapy for Advanced Hepatocellular Carcinoma: Decisions in the Real World

Learn how a “watershed” clinical trial in 2020 completely overturned a decade of standard care for liver cancer. In this inaugural episode of the BackTable 2026 HCC Creator Weekend™ , medical oncologists Dr. John Rahi, Dr. Craig Lockhart, and Dr. Lingling Du review the evolution of first-line systemic therapy for hepatocellular carcinoma (HCC), highlighting immune checkpoint inhibitors as a major change from the TKI era.
Tumor Board # 56Apr 21, 2026Breast Cancer Precision Medicine: Biomarkers & Treatments

Here’s a practical guide on how biomarkers can guide treatment and cut costs for your breast cancer patients. In this episode of the BackTable Tumor Board Podcast, Dr. Lindsay Peterson and Dr. Jessica Trevino Jones review the role of precision medicine and biomarkers in early-stage and metastatic disease, specifically in breast cancer.
Tumor Board # 55Apr 14, 2026Updates in Colorectal Cancer Management: Insights from ASCO GI

How will the newest colorectal cancer trial results discussed at the 2026 ASCO GI Cancers Symposium in San Francisco impact patient care and therapeutic strategies? Medical oncologists Dr. Shruti Patel and Dr. Jun Gong dissect evidence from multiple practice-changing studies, translating complex data into practical recommendations.
Tumor Board # 51Mar 17, 2026Intratumoral Immunotherapy Injections for Melanoma

When standard-of-care checkpoint blockade fails in metastatic melanoma, how can oncologists and interventional radiologists join forces to turn around patient outcomes? In this episode of the BackTable Podcast, medical oncologist Dr. Jennifer McQuade and interventional radiologist Dr. Rahul Sheth join host Dr. Tyler Sandow to discuss the growing evidence for intratumoral oncolytics as a therapeutic strategy for frontline immunotherapy-refractory melanoma and the interdisciplinary work that is required for successful implementation in practice.
ENT & Allergy # 263Mar 3, 2026Immunotherapy for Adults with RRP

Recurrent respiratory papillomatosis (RRP) has long been managed with repeated surgical debulking, sometimes requiring dozens of procedures over a lifetime. In this episode of BackTable, Dr. Aaron Friedman and guest host Dr. Stephen Schoeff discuss a major shift in care: immune-directed therapy targeting HPV 6 and 11.
Urology # 287Jan 30, 2026Urothelial Carcinoma: Understanding ctDNA & Precision Medicine

Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in bladder cancer continue to evolve, emerging tools like circulating tumor DNA (ctDNA) are playing a bigger role in how clinicians assess recurrence risk and tailor treatment. In this episode of BackTable Tumor Board, host Alan Tan, medical oncologist at Vanderbilt-Ingram Cancer Center, is joined by bladder cancer experts Dr. Amanda Nizam and Dr. Brad McGregor to discuss recent advances in the diagnosis and treatment of urothelial carcinoma.
ENT & Allergy # 258Jan 27, 2026Understanding Sublingual vs. Subcutaneous Immunotherapy

When allergy meds aren’t enough, how do you choose the form of immunotherapy that will work best for your patient? Board-certified allergist-immunologist Dr. Nikhila Schroeder and host Dr. Basil Kahwash answer that question and more in this episode of the BackTable ENT Podcast.
Tumor Board # 45Jan 27, 2026Urothelial Carcinoma: Understanding ctDNA & Precision Medicine

Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in bladder cancer continue to evolve, emerging tools like circulating tumor DNA (ctDNA) are playing a bigger role in how clinicians assess recurrence risk and tailor treatment. In this episode of BackTable Tumor Board, host Alan Tan, medical oncologist at Vanderbilt-Ingram Cancer Center, is joined by bladder cancer experts Dr. Amanda Nizam and Dr. Brad McGregor to discuss recent advances in the diagnosis and treatment of urothelial carcinoma.
Vascular & IR # 595Dec 5, 2025Lung Cancer Staging & Systemic Therapies: Recent Advancements

How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung cancer patient’s treatment plan? In this episode of the 2025 NSCLC Creator Weekend™ series, our tumor board discusses the complexities of lung cancer treatment, including new systemic therapies, lung cancer staging, and the role of molecular diagnostics and liquid biopsies.
Vascular & IR # 591Nov 21, 2025NSCLC Tumor Board Discussion: Considerations for Oligometastatic Disease

When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first? Part two of the 2025 NSCLC Creator Weekend™ series focuses on a complex case involving a 75-year-old woman with a history of breast malignancy, presenting with new dyspnea and a large mass in the left lower lobe.
Tumor Board # 36Nov 18, 2025Lung Cancer Staging & Systemic Therapies: Recent Advancements

How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung cancer patient’s treatment plan? In this episode of the 2025 NSCLC Creator Weekend™ series, our tumor board discusses the complexities of lung cancer treatment, including new systemic therapies, lung cancer staging, and the role of molecular diagnostics and liquid biopsies.
Tumor Board # 35Nov 14, 2025NSCLC Tumor Board Discussion: Considerations for Oligometastatic Disease

When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first? Part two of the 2025 NSCLC Creator Weekend™ series focuses on a complex case involving a 75-year-old woman with a history of breast malignancy, presenting with new dyspnea and a large mass in the left lower lobe.